Wave Life Sciences initiated with a Buy at JonesResearch

JonesResearch analyst Catherine Novack initiated coverage of Wave Life Sciences with a Buy rating and $12 price target. Wave’s portfolio contains diverse assets that give investors exposure to multiple therapeutic areas while maintaining a core competency in RNA medicine, the analyst tells investors in a research note. The firm says the company’s PRISM platform is a “key differentiator from other RNA companies, combining unique RNA chemistry and synthetic methods to optimize PK properties.”